Literature DB >> 16614009

Fulminant Devic disease successfully treated by lymphocytapheresis.

I Nozaki, T Hamaguchi, K Komai, M Yamada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16614009      PMCID： PMC2077763          DOI： 10.1136/jnnp.2005.086306

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

1.  Use of lymphoplasmapheresis or plasmapheresis in the management of acute renal allograft rejection.

Authors:  S Kleinman; M Nichols; F Strauss; D Goldfinger
Journal:  J Clin Apher       Date:  1982       Impact factor: 2.821

2.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

Authors:  Vanda A Lennon; Dean M Wingerchuk; Thomas J Kryzer; Sean J Pittock; Claudia F Lucchinetti; Kazuo Fujihara; Ichiro Nakashima; Brian G Weinshenker
Journal:  Lancet       Date:  2004 Dec 11-17       Impact factor: 79.321

3.  Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-I-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis.

Authors:  H Ochi; X M Wu; M Osoegawa; I Horiuchi; M Minohara; H Murai; Y Ohyagi; H Furuya; J Kira
Journal:  J Neuroimmunol       Date:  2001-10-01       Impact factor: 3.478

4.  Activation of humoral immunity and eosinophils in neuromyelitis optica.

Authors:  Jorge Correale; Marcela Fiol
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

5.  Lymphocytaplasmapheresis in Devic's syndrome.

Authors:  A J Aguilera; T J Carlow; K J Smith; T L Simon
Journal:  Transfusion       Date:  1985 Jan-Feb       Impact factor: 3.157
  5 in total
  8 in total

1.  Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications.

Authors:  Romain Marignier; Pascale Giraudon; Sandra Vukusic; Christian Confavreux; Jérôme Honnorat
Journal:  Ther Adv Neurol Disord       Date:  2010-09       Impact factor: 6.570

2.  Neuromyelitis optica.

Authors:  William M Carroll; Kazuo Fujihara
Journal:  Curr Treat Options Neurol       Date:  2010-05       Impact factor: 3.598

Review 3.  Neuromyelitis optica: diagnosis, pathogenesis, and treatment.

Authors:  Bruce Cree
Journal:  Curr Neurol Neurosci Rep       Date:  2008-09       Impact factor: 5.081

Review 4.  [Neuromyelitis optica].

Authors:  S Jarius; B Wildemann
Journal:  Nervenarzt       Date:  2007-12       Impact factor: 1.214

5.  Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices.

Authors:  Amer Awad; Olaf Stüve
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

6.  Plasma exchange in severe attacks of neuromyelitis optica.

Authors:  Mickael Bonnan; Philippe Cabre
Journal:  Mult Scler Int       Date:  2012-02-12

Review 7.  MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder.

Authors:  Giordani Rodrigues Dos Passos; Luana Michelli Oliveira; Bruna Klein da Costa; Samira Luisa Apostolos-Pereira; Dagoberto Callegaro; Kazuo Fujihara; Douglas Kazutoshi Sato
Journal:  Front Neurol       Date:  2018-04-04       Impact factor: 4.003

8.  Role of low plasma volume treatment on clinical efficacy of plasmapheresis in neuromyelitis optica.

Authors:  Akshay Batra; Sundar Periyavan
Journal:  Asian J Transfus Sci       Date:  2017 Jul-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.